355 related articles for article (PubMed ID: 23029232)
1. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
[TBL] [Abstract][Full Text] [Related]
2. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
3. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immunity induced by M2e of influenza virus.
Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
[TBL] [Abstract][Full Text] [Related]
5. [Construction and immunogenicity of recombinant bacteriophage T7 vaccine expressing M2e peptides of avian influenza virus].
Xu H; Wang YW; Tang YH; Zheng QS; Hou JB
Bing Du Xue Bao; 2013 Jun; 29(4):376-81. PubMed ID: 23895000
[TBL] [Abstract][Full Text] [Related]
6. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
7. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
8. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
[TBL] [Abstract][Full Text] [Related]
9. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
10. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
[TBL] [Abstract][Full Text] [Related]
11. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
[TBL] [Abstract][Full Text] [Related]
12. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
13. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
[TBL] [Abstract][Full Text] [Related]
14. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
15. An influenza A virus vaccine based on an M2e-modified alphavirus.
Krishnavajhala HR; Williams J; Heidner H
Arch Virol; 2018 Feb; 163(2):483-488. PubMed ID: 29079954
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
[TBL] [Abstract][Full Text] [Related]
17. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
18. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
[TBL] [Abstract][Full Text] [Related]
19. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
20. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]